Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Jun
01
Today In Oncology
PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer
Adjuvant Selpercatinib Improves Event-Free Survival in RET-Positive Early-Stage NSCLC
Implanted Cesium-131 Tiles Improve Local Control and Survival in Patients With Resected Brain Metastases
Many Patients With Limited Sentinel Node–Positive Breast Cancer Can Safely Avoid Axillary Dissection, Study Shows
Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo